There is still much to be learned about developing clinically successful checkpoint drugs and combination strategies. The ongoing torrent of successes and setbacks from the leaders in the field have undoubtedly proven this.
At the heart of these challenges there is a mechanistic understanding of the body’s immune-based anti-tumor responses. The ICI-IO Combinations Summit focuses exclusively on how to leverage this integral system to deliver maximum clinical benefit, through the combinations of immune checkpoint modulators with immuno-oncology therapies.
The meeting will deliver granular insights on the preclinical, translational and clinical challenges that drug developers face when seeking out combination partners for their ICI drugs. Rather than a general overview of the IO space, a combination of case-study based stories of successes and failures partnered with insight-led discussion will you with provide solutions to intricate IO challenges.
Join us in breaking the current cycle of clinical failures and establish a strategy that means entering the clinical with the confidence to achieve success.
For more information, download the full event guide.